NVTA.Q Stock Overview
A medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Invitae Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0004 |
| 52 Week High | US$1.25 |
| 52 Week Low | US$0.000001 |
| Beta | 2.8 |
| 1 Month Change | -42.86% |
| 3 Month Change | -76.47% |
| 1 Year Change | -99.97% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely
Dec 20
Invitae: Revenue Troubles Build
Aug 09Invitae Is Treading In Competitive Waters
Jul 16Invitae Corporation's (NYSE:NVTA) Prospects Need A Boost To Lift Shares
Jun 26Invitae: What Happened At The JP Morgan Health Conference
Jan 19Invitae guides Q4 revenue above estimates
Jan 09Invitae Likely Hasn't Reached The Bottom Yet
Dec 15Invitae: This Turnaround Could Be Painful
Nov 15Invitae GAAP EPS of -$1.27 misses by $0.43, revenue of $133.54M beats by $2.16M
Nov 08Invitae Stock: Losses And Debt Suggest Bearish Sentiment Is Deserved
Sep 22Why Invitae Corporation Could Underperform
Aug 17Invitae maintains 2022 financial guidance as Q2 results beat on top and bottom lines
Aug 09Shareholder Returns
| NVTA.Q | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | 1.3% |
| 1Y | -100.0% | -11.2% | 8.2% |
Return vs Industry: NVTA.Q underperformed the US Healthcare industry which returned 8.6% over the past year.
Return vs Market: NVTA.Q underperformed the US Market which returned 15.9% over the past year.
Price Volatility
| NVTA.Q volatility | |
|---|---|
| NVTA.Q Average Weekly Movement | 642.7% |
| Healthcare Industry Average Movement | 7.8% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: NVTA.Q's share price has been volatile over the past 3 months.
Volatility Over Time: NVTA.Q's weekly volatility has increased from 571% to 643% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1,700 | Ken Knight | www.invitae.com |
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners.
Invitae Corporation Fundamentals Summary
| NVTA.Q fundamental statistics | |
|---|---|
| Market cap | US$114.60k |
| Earnings (TTM) | -US$1.44b |
| Revenue (TTM) | US$481.58m |
0.0x
P/S Ratio0.0x
P/E RatioIs NVTA.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVTA.Q income statement (TTM) | |
|---|---|
| Revenue | US$481.58m |
| Cost of Revenue | US$350.95m |
| Gross Profit | US$130.64m |
| Other Expenses | US$1.57b |
| Earnings | -US$1.44b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.03 |
| Gross Margin | 27.13% |
| Net Profit Margin | -299.14% |
| Debt/Equity Ratio | -124.7% |
How did NVTA.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/05 20:02 |
| End of Day Share Price | 2024/08/02 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Invitae Corporation is covered by 14 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| Steven Wardell | Chardan Capital Markets, LLC |
| Daniel Leonard | Credit Suisse |